Abstract

The extra domain A (ED A) of fibronectin has been identified as a tumor vessel specific neovascular marker in glioma. Antibody based vascular targeting against ED A of fibronectin allows precise accumulation of photosensitizer in glioma microvasculature and thereby promises to overcome drawbacks of current photodynamic therapy (PDT) for glioma treatment. Our aim was to characterize microcirculatory consequences of F8-small immunoprotein (SIP) mediated PDT by intravital microscopy (IVM) and to analyze the effects on glioma growth. For IVM SF126 glioma cells were implanted into dorsal skinfold-chamber of nude mice. PDT was performed after intravenous injection of photosensitizer (PS)-coupled F8-SIP or PBS (n=4). IVM was performed before and after PDT for 4days. Analysis included total and functional (TVD, FVD) vessel densities, perfusion index (PI), microvascular permeability and blood flow rate (Q). To assess tumor growth SF126 glioma cells were implanted subcutaneously. PDT was performed as a single and repetitive treatment after PS-F8-SIP injection (n=5). Subcutaneous tumors were treated after uncoupled F8-SIP injection as control group (n=5). PDT induced microvascular stasis and thrombosis with reduced FVD (24h: 115.98±0.7 vs. 200.8±61.9cm/cm(2)) and PI (39±11 vs. 70±10%), whereas TVD was not altered (298±39.2 vs. 278.2±51cm/cm(2)). Microvascular dysfunction recovered 4days after treatment. Microvascular dysfunction led to a temporary reduction of glioma growth in the first 48h after treatment with complete recovery 5days after treatment. Repetitive PDT resulted in sustained reduction of tumor growth. F8-SIP mediatedPDT leads to microvascular dysfunction and reduced glioma growth in a preclinical glioma model with recovery of microcirculation 4days after treatment. Repetitive application of PDT overcomes microvascular recovery and leads to prolonged antiglioma effects.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.